期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

4-苯胺喹唑啉类化合物的合成与抗癌活性初步研究 被引量：2

Syntheses of 4-Quinazoline Derivatives and Primary Study of Their Anti-Tumor Activity
原文传递
导出
摘要 以香兰素为起始原料,经过氰基化、醚化、硝化、还原和环化反应,合成了一系列新型的含二苯乙烯结构单元的4-芳胺基喹唑啉类衍生物。化合物的结构经IR、1H NMR和13C NMR确证,并采用MTT法对SMMC-7721(人肝癌细胞)、SK-OV-3(人卵巢癌细胞)等几种常见肿瘤细胞进行了初步体外抗肿瘤活性实验。结果表明合成的化合物均具有良好的抑制肿瘤细胞生长的作用。 Nine kinds of 4-arylaminoquinazoline derivative were prepared using vanillin as the starting material by a step procedures of conversion including eyanation, nitration, reduction, reaction with DMF-DMA, and finally cyelization with arylamines via Dimroth rearrangement. Their structures were characterized with IR, 1H NMR and 13C NMR. The anti-tumor activities of these compounds on SMMC-7721, SK-OV-3 and some other cells were tested preliminarily by the MTT method in vitro experiment. The results indicated that these compounds possess good antitumor effects.
作者 高宏亮 王留昌 徐宏江 张喜全 刘仁杰 李宝林
机构地区 教育部药用资源与天然药物化学重点实验室陕西师范大学化学化工学院 正大天晴药业集团股份有限公司
出处 《化学通报》 CAS CSCD 北大核心 2014年第10期974-979,共6页 Chemistry
基金 国家自然科学基金项目(21272144)资助
关键词 香兰素 4-芳氨基喹唑啉 喹唑啉 抗肿瘤活性 Vanillin, 4-Arylaminoquinazoline, Quinazoline, Anti-tumor activity
分类号 O626.323 [理学—有机化学] TQ460.1 [化学工程—制药化工]
  • 相关文献

参考文献18

  • 1S A Aaronson. Science,1991, 254:1146 - 1153.
  • 2A Ullrich, J Schlessinger. Cell, 1990; 61 : 203 - 212.
  • 3N Prenzel, O M Fischer, S Streit et al. Endoer-Relat. Cancer, 2001, 8:11 -31.
  • 4J Mendelsohn, J Baselga. J. Clin. Oneol. , 2003, 21:2787 - 2799.
  • 5N Minkovsky, A Bevezov. Curr. Opin. Invest. Drugs, 2008, 9:1336-1346.
  • 6J Y Lee, Y K Park, S H Seo et al. Archiv der Pharmazie, 2001, 334(11): 3-57 -360.
  • 7J F Vansteenkiste. Expert Rev. Anticancer Ther. , 2004, 4 (1):5-17.
  • 8M Jang, J M Pezzuto. Drugs Exp. Clin. Res. , 1999, 25(2/ 3) : 65 -77.
  • 9陈国良,耿春梅,刘湘永.白藜芦醇衍生物及类似物的研究进展[J].药学进展,2006,30(4):145-150. 被引量：15
  • 10M Cushman, D Nagarathnam, G D Dhanapalan et al. J. Med. Chem. ,1991, 34: 2579-2588.

二级参考文献47

  • 1李铭东,曹萌,吉民.盐酸埃洛替尼的合成[J].中国医药工业杂志,2007,38(4):257-259. 被引量：10
  • 2Ali M A,Kondo K,Tsuda Y.Synthesis and nematocidal activity of hydroxystilbenes[J].Chem Pharm Bull,1992,40(5):1130-1136.
  • 3张学景,朱杰,熊晓云,等.Synthesis of resveratrol and resveratrol trinicotinate[J].J Chinese Pharm Sci,2004,13(1):10-13.
  • 4Kim S,Ko H,Park J E,et al.Design,synthesis,and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors[J].J Med Chem,2002,45(1):160-164.
  • 5De Medina P,Casper R,Savouret J,et al.Synthesis and biological properties of new stilbene derivatives of resveratrol as new selective aryl hydrocarbon modulators[J].J Med Chem,2005,48(1):287-291.
  • 6Potter G A,Pattersonl L H,Wanoghol E,et al.The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1[J].Br J Cancer,2002,86(5):774-778.
  • 7Murias M,Handler N,Erker T,et al.Resveratrol analogues as selective cyclooxygenase-2 inhibitors:synthesis and structure-activity relationship[J].Bioorg Med Chem,2004,12(21):5571-5578.
  • 8Lu J B,Ho C T,Ghai G,et al.Resveratrol analog,3,4,5,4'-tetrahydroxystilbene,differentially induces proapoptotic p53/Bax gene expression and inhibits the growth of transformed cells but not their normal counterparts[J].Carcinogenesis,2001,22(2):321-328.
  • 9Murias M,Jager W,Handler N,et al.Antioxidant,prooxidant and cytotoxic activity of hydroxylated resveratrol analogues:structure-activity relationship[J].Biochem Pharmacol,2005,69(6):903-912.
  • 10Sala G,Minutolo F,Macchia M,et al.Resveratrol structure and ceramide-associated growth inhibition in prostate cancer cells[J].Drugs Exp Clin Res,2003,29(5-6):263-269.

共引文献20

同被引文献34

  • 1任晓岚,汪鑫,李志裕,尤启冬.表皮生长因子受体(EGFR)酪氨酸激酶抑制剂的研究进展[J].中国新药杂志,2005,14(7):821-826. 被引量：31
  • 2Shang H, Chen H,Zhao D M ,et al. Synthesis and Biological Evaluation of 4a/4fl-Imidazolyl Podophyllotoxin Analogues as Antitumor Agents [ J ]. Arch Pharm Chem Life Sci ,2012,345 (1) :43-48.
  • 3Laskin J J,Sandler A B. Epidermal Growth Factor Receptor A Promising Target in Solid Tumours[ J]. Cancer Treat Rev, 2004,30(1) :1-17.
  • 4Vlahovic G, Crawford J. Activation of Tyrosine Kinases in Cancer [ J ]. O ncologist,2003,8 ( 6 ) : 531-538.
  • 5Ravaud A, Hawkins R, Gardner J P, et al. Lapatinib Versus Hormone Therapy in Patients with Advanced Renal CellCarcinoma: A Randomized Phase III Clinical Trial[ J ]. J Clin 0ncoi,2008,26 (14) :2285-2291.
  • 6Carter M C, Cockerill G S, Guntrip S B,et aL Bicyclic Heteroaromatic Compounds [ Quinazolinamines, Pyridopyri-midines, and Analogs] Useful as Protein Tyrosine Kinase Inhibitors. WO,9935146A1. [ P] , 1999-07-15.
  • 7Sato T, Watanabe H, Tsuganezawa K, et al. Identification of Novel Drug-resistant EGFR Mutant Inhibitors by I-nsilico Screening Using Comprehensive Assessments of Protein Structures[ J]. Bioorg Med Chem,2012,20(12) :3756-3767.
  • 8Morphy R. Selectively Nonselective Kinase Inhibition: Striking the Right Balance [ J ]. J Med Chem,2010153 (4) : 1413-1437.
  • 9Tsuda Y, Hanajima M, Matsuhira N, et al. Regioselective Mono-Oxidation of Non-protected Carbohydrates by Brominolysis of the Tin Intermediates [ J ]. Chem Pharm Bull, 1989,37 ( 9 ) : 2344-2350.
  • 10Gong S W, He H F,Zhao C Q, et al. Convenient Deoxygenation of Aromatic Ketones by Silica-Supported Chitosan Schiff Base Palladium Catalyst[J]. Synth Commun,2012,42(4):574-581.

引证文献2

二级引证文献4

化学通报
2014年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部